Anti-Microbial Peptides and Their Speculative Role in Periodontitis

Vinita Ved¹ and Gabriela Fernandes²*

¹Dental Intern, YMT Dental College, India
²Department of Oral Biology, School of Dental Medicine, USA

Received: November 11, 2017; Published: November 30, 2017

*Corresponding author: Gabriela Fernandes, Department of Oral Biology, SUNY Buffalo, New York, USA; Email: gfernand@buffalo.edu

Abstract
Antimicrobial Peptides (AMPs) are present in the oral cavity in the form of defensins and human cathelicidin LL-37 (from neutrophil granules) and histatins along with pdefensins 1 and 2 (from salivary glands and gingival epithelial cells). The oral micro flora organisms that play an important role in the pathogenesis of periodontal disease are opportunistic pathogens, that are highly proteolytic and this activity is known to contribute to nutrient acquisition, tissue destruction and de-regulation of inflammatory responses. Furthermore, the production of proteases enables oral bacteria to evade killing by antimicrobial peptides, thus contributing to the virulence of such opportunistic pathogens, which could have implications for the use of antimicrobial peptides as therapeutic agents to treat periodontal disease. Hence, this review summarizes the suggestive role of AMPs in periodontal disease.

Keywords: Immunity; Anti-Microbial Peptides; Periodontitis

Abbreviations: AMPs: Antimicrobial Peptides, LAP: Lingual Antimicrobial Peptide, HNP: Human Neutrophil Peptide; hBD: Human Beta-Defensins

Introduction
Humans often require a multilayered defense mechanism to function smoothly and combat micro-organisms and pathogens. The fundamental guarding complex for almost all human organisms comprises of innate immunity [1]. It is this defense mechanism that helps discern a wide variety of agents, known as pathogens, and distinguish them from the organism’s own healthy tissue [1]. The oral cavity is a manifold interaction where sundry organisms, both commensal and destructive types, intercommunicate and escalate in the environment [2]. The noteworthy quality of the oral cavity lies in the presence of specialized interaction between tooth (hard tissue) presenting itself from the underlying gingival epithelium (soft tissue).

Ideally in the oral cavity, the tooth structure often encompasses a layer of pathogenic biofilm termed “Dental plaque,” that compromises the surrounding epithelium via its incessant exposure to microorganisms [3]. This is when the comeback of the epithelium to these insults determines the overall condition of the gingival sulcus. It is evident that the oral epithelium works in several ways for the conservation of the underlying tissues. As a physical barricade, it can counter unbroken microbial oppositions from dental plaque by the production of chemokines, cytokines, and antimicrobial peptides (AMPs), which enhance inflammation and immune response in oral epithelial tissues [4]. These epithelial antimicrobial peptides are considered to be paramount for the innate immunity of the host [5].

AMPs are also prime contributors that enable the stabilization between health and disease in this complex ecosystem [6]. Exhibiting a wide spectrum of antimicrobial activity against gram-positive and gram-negative bacteria, yeasts and certain viruses, they possess the ability to prevent various oral periodontal diseases including bacteria, fungal and viral infections [7]. The reaction involving multiple AMPs to a single pathogen of infection prevents the consequences of antimicrobial resistance. Several families of antimicrobial peptides have been studied in the oral cavity which includes α-defensins, β-defensins, calprotectin, adrenomedullin, histatins, and cathelicidin [8]. The aim of this review paper is to view the crucial role of these molecules against periodontal diseases and its function in host immunity. The article also sheds light on the mechanism of action and the types of identified AMPs.

Types of Anti-Microbial Peptides involved in Periodontitis

The AMPs react to the periodontopathogenic bacteria in a synergistic manner, whereby they secrete chemical innate immunity...
signal molecules like interleukin, chemokine and cytokines that attract neutrophils at the site and caution the host response [7]. Conducive with the amount of microbial exposure, they also produce natural AMPs and proteins. By acting as an integral part of the hosts natural innate environment, the oral epithelium, polymorph nuclear leukocytes (neutrophils) and saliva, all concurrently and solitarily bestow to this response [9,10]. These responses involve several salivary antimicrobial peptides, the β-defensins manifested in the epithelium, the α-defensins expressed in neutrophils, and the cathelicidin, LL-37, in both epithelium and neutrophils [11-13].

**Defensins**

The first AMPs identified in the oral epithelium were defensin, Lingual Antimicrobial Peptide (LAP) [14]. The defensin families are prominent AMPs that reside in the host environment, which include the alpha-defensins (human neutrophil peptide; HNP) and human beta-defensins (hBD) [15]. Defensins are stored in secretory granules, with expanding levels observed during periodontitis (Figure 1). Their mechanism of action involves destroying phagocytosed bacteria upon fusion with the secretory granules from the phagocytic vacuoles they reside in [16]. Being a part of the host’s natural environment, expressed in gingiva, tongue, salivary glands and mucosa, they are present in conditions like oral inflammation, carcinomas, etc. Defensins have also shown to inhibit LPS-stimulated inflammatory responses in host cells, which is a primary causal mechanism in the pathogenesis of periodontal disease [16]. Defensins are allocated into subfamilies of α- and β-defensins. Human beta-defensins (hBD) are elementally revealed in epithelial cells, while alpha-defensin are predominantly expressed in neutrophils [17]. Segregated in terms of their cysteine motifs, dually both of them share a homogenous secondary structure, and are opulent in cationic residues [18,19].

**Table 1:** Summary of the role of defensins.

<table>
<thead>
<tr>
<th>Type of AMP</th>
<th>Site</th>
<th>Role</th>
<th>Association with oral diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>alpha-defensins[7,14,24,39] (human neutrophil peptide; hNP)</td>
<td>Neutrophils</td>
<td>Antibacterial</td>
<td>Oral inflammation</td>
</tr>
<tr>
<td></td>
<td>hNP-1</td>
<td>Antiviral</td>
<td>Periodontal conditions including chronic and aggressive periodontitis showing gingival or mucosal inflammation or loose exfoliating teeth.</td>
</tr>
<tr>
<td></td>
<td>hNP-2</td>
<td>Antifungal</td>
<td>Oral cancer</td>
</tr>
<tr>
<td></td>
<td>hNP-3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>beta-defensins[16,22] (hBD)</td>
<td>Gingival crevicular fluid present in the gingival sulcus; α-defensins, HNP-1–3, are readily detected in the junctional epithelium.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Around 99% of hNP 1-3 is found in the saliva. hNP-4 levels are lower hNP-5 and hNP-6 are not found in the oral cavity and are expressed in enteric system. hNP levels are seen to be higher with oral diseases like oral lichen plans, leukoplakia, SCC.

hBD-1 and hBD-2: Found in supra basal layers of stratified epithelium. They are absent in junctional epithelium.

hBD-3: It is expressed in undifferentiated epithelial cells, which is within the basal layer. hBD-1 is constitutively expressed hBD-2 and hBD-3 are unregulated in inflamed skin and other epithelial cells, by bacterial and pro-inflammatory stimuli. Low levels of unstimulated hBD-2 have been observed.

Principle AMPs holding major role in initial innate comeback against bacterial agents in tissues. Part of protective barrier in periodontal situations.

Anti-fungal

Anti-viral

Additionally, they play a role in wound healing by rejuvenating the damaged epithelium.

They function as both pro-inflammatory and anti-inflammatory agents in pathogenesis of diseases.

Chemical appeal of dendritic cells and t cells, macrophages hBD-3 acts as a mediator to signal the underlying cells in the connective tissue.

Up-regulated levels hoods have been observed in inflammatory situations and infections.

Having higher levels at gingival margins close to plaque, hBD-1 and hBD-2 are expressed in non-infamed tissues.

Infections and Inflammatory situations like Dental Caries, periodontitis, keratinocytic differentiation, oral cancers

Cathelicidin (LL-37)

Used markedly as one of the predominant identifying tools in inflammatory periodontal disorders, this class of AMPs incorporates a mature peptide and cathelin domain. It is a multifunctional peptide, comprising of 37 amino acids [24]. Active against gram positive and gram negative bacteria, it directly binds to the LPS of bacterial cells, and is native to the oral cavity in several sites, including the buccal and tongue mucosa, gingival crevicular fluid [24]. By activating antigen-presenting cells, it presents as a hemoattractant for immune cells, including monocytes, T cells, etc. There is a specific correlation amongst multiplication in LL-37 levels and periodontal inflammation [25-28]. It is also known to cause an elevation in mucosal thickness in the gingiva. Furthermore, studies have also demonstrated its tissue specific effects on cancer cells [27,28]. Their mode of action involves intracellular killing of the phagosomes after phagocytosis of the bacteria, where the AMP in the neutrophil is severed into a fully developed peptide (Table 2).

<table>
<thead>
<tr>
<th>Type of AMP</th>
<th>Site</th>
<th>Role</th>
<th>Association with oral diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cathelicidin (LL-37)</td>
<td>Found in neutrophils as well as epithelial cells Saliva</td>
<td>Primary antibacterial- Gram positive and gram negative bacteria Diagnostic tool in Inflammatory periodontal disorders</td>
<td>Increased levels observed in chronic periodontitis, inflammatory conditions. Tissue specific in terms of cancer cells</td>
</tr>
<tr>
<td>Histatins</td>
<td>Gingival crevicular fluid in gingival sulcus</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Histatins

These AMPs are exclusively resided in the salivary glands, i.e. parotid and submandibular salivary duct cells. Histamine 1, 3 and 5 are found to be predominant of the total histatin proteins (85%) in the saliva [29-32]. They have a major role in fungicidal activity, having a noteworthy role in oral candidiasis restraint, especially histatin-5, which is the most significantly active against candida species as well as bactericidal activities against Porphyromonas gingivalis and Streptococcus mutans, which play a key role in the etiopathogenesis of periodontal disease and dental caries ,respectively [30,32]. Significant linkage occurs between xerostomia and oral candidiasis. It is also noteworthy that the anti-fungal action is shared between alpha-defensin and histatin, which require ATP transport found in active mitochondria.

Secretory Leuko Protease Inhibitor (SLPI)

Another AMP identified from the parotid salivary gland is SLPI. Manifested in neutrophils, epithelial cells and salivary glands, this
protein suggests anti-inflammatory action at the site of infection [33]. Supplementary to having fungicidal action, it has shown to inhibit contamination of human monocytes and is also conveyed in oral tumor tissues as well as inhibition of the HIV virus [34,35]. SLPI is associated with wound repair and its expression is elevated following wound healing [35,36]. The elevated quantity of SLPI following periodontal treatment is an evidence of inflammation resolution activities [36].

**Summary**

The capacity of these inborn antibiotics is only at its inception of its recognition, as amplified natural announcement or as novel relieving agents [8,37]. This class of proteins is a captivating target for periodontal diseases [37]. In times of periodontal disease, Table 3: Significance of AMPs.

Moreover, Antimicrobial peptides are potentially important as novel therapeutic agents against periodontal disease diagnosis and potential treatment and probably show most immediate promise for development as topical adjuvant agents in conjunction with conventional periodontal therapy in the treatment of periodontal disease. This makes them promising for oral diseases, as topical application of antimicrobial agents is easy and appropriate, and their use would not contribute to resistance to antibiotics normally used in treatment of more life-threatening bacterial infections. All these findings will have direct implications for new understanding of oral innate immune responses and the development of potential new and innovative therapeutic interventions for periodontal disease.

**References**


